DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA) a biopharmaceutical company focused on the
development of novel treatments for Type 1 and Type 2 diabetes announces the
formation of a development advisory group for its DM-199 and DM-204 products for
the treatment of Type 1 and Type 2 diabetes. The advisory group consists of Dr.
Joy Cavagnaro, Dr. Patrick Gearing, and Mr. Larry Johnson; industry experts in
the areas of pharmacology and toxicology, manufacturing and regulatory affairs.


"We are pleased to welcome Dr. Cavagnaro, Dr. Gearing, and Mr. Johnson to our
product development advisory group. They bring together significant industry
experience in protein-based diabetes therapeutics from development, through
regulatory approval and commercialization. They have all worked at or closely
with the US Food and Drug Administration (FDA) with numerous biotechnology and
pharmaceutical companies on successful drug approvals and are now guiding
DiaMedica towards hitting its product development milestones," said Rick Pauls,
Chief Executive Officer of DiaMedica.


Biographies:

Joy Cavagnaro, PhD, DABT, ATS. Pharmacology and Toxicology

Dr. Cavagnaro assists DiaMedica in the design and implementation of pre-clinical
toxicology studies to access safety, tolerability and pharmacokinetics of
protein-based therapies. Dr. Cavagnaro is President and Founder of Access BIO
consultancy specializing in pre-clinical pharmacology and toxicology programs
and science-based regulatory strategies to support Phase I clinical trials. She
has over 25 years of experience in biotech. Previously, Dr. Cavagnaro served as
Vice President of Regulatory Affairs at Human Genome Sciences, Inc. and spent
close to a decade at the FDA Center for Biologics Evaluation and Research
(CBER), including serving as Senior Pharmacologist & Director of Quality
Assurance Office of the Center Director. While at the FDA, Dr. Cavagnaro was
instrumental in establishing key policy, and guidance documents for
biologic-based products and served as rapporteur for the "ICH S6 Guidance on
Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals".
Additional responsibilities included review of 100s of INDs and 6 licensing
applications. Prior to the FDA, Dr. Cavagnaro was a Senior Staff Scientist,
Department of Toxicology at Covance, overseeing pre-clinical pharmacology and
toxicology client studies of biotechnology products. Dr. Cavagnaro is a
Diplomate American Board of Toxicology and a Fellow Academy of Toxicological
Sciences. www.accessbio.com


Patrick Gearing, PhD. cGMP Manufacturing and CMC Product Development

Dr. Gearing provides critical technical and regulatory advice on the
manufacturing of cGMP quality biologic-based therapeutics to DiaMedica. Dr.
Gearing has a well-established track record of working with clients to achieve
successful process development and manufacture of cGMP protein therapeutics
appropriate for clinical trials. Dr. Gearing routinely works with world-leading
contract manufacturing organizations (CMOs), using his 19 years of industry
experience to help clients overcome development and manufacturing challenges
unique to each protein. Dr. Gearing has product development experience in
several regulatory jurisdictions including the US, Europe, Japan, Canada and
Australia, thereby being able to provide sound product development advice. Prior
to founding Ridge Biotechnology, Dr. Gearing was Director of Pharmaceutical
Development and Quality Systems at Seattle Genetics, Inc., helping to guide the
development of their monoclonal cancer antibody pipeline. Additional industry
experience also includes positions at Coulter Pharmaceutical, Inc., PDL
BioPharma, Inc., and Immunex Corp. (Amgen). www.ridgebiotechnology.com


Larry Johnson, MSc. Regulatory Affairs

Mr. Johnson provides expertise in the interaction with regulatory agencies,
including the FDA, EMA, and Health Canada, to achieve clinical and marketing
approvals. Mr. Johnson has over 35 years of experience in working with over 50
international and US-based pharmaceutical companies at all stages of product
development (pre-clinical, clinical and market approval stages) to expedite
development. This has included assisting with the filing of over 30 INDs, NDAs
for drug products, and PLAs for biologic-based products. He has also
participated in several hundred meetings with the FDA and other regulatory
agencies on behalf of clients. Additionally, Mr. Johnson assists companies in
the development of compliance procedures, standards and documentation (GLP, GCP,
GMP) appropriate to the stage of product development. Previously, Mr. Johnson
was Responsible Head and Director of Regulatory Affairs at Amgen, Inc., helping
to obtain its first product approval; he continued working closely with the
company for over 16 years as a regulatory consultant. Mr. Johnson has also been
employed by Abbott Laboratories and the US Centers for Disease Control.
www.biofinity.org


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control.


DiaMedica is also developing a monoclonal antibody, DM-204. In pre-clinical
studies, DM-204 significantly improved glucose control and decreased blood
pressure.


The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024